ATENOLOL; CHLORTHALIDONE - Generic Drug Details

What are the generic sources for atenolol; chlorthalidone and what is the scope of patent protection?

Atenolol; chlorthalidone is the generic ingredient in three branded drugs marketed by Aiping Pharm Inc, Aurobindo Pharma Usa, Nostrum Labs, Novitium Pharma, Pliva, Sun Pharm Industries, Unichem, Watson Labs, Zydus Pharms, and Twi Pharms, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

Ten suppliers are listed for this compound.

Summary for ATENOLOL; CHLORTHALIDONE

US Patents:	0
Tradenames:	3
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	4
Patent Applications:	76
DailyMed Link:	ATENOLOL; CHLORTHALIDONE at DailyMed

Recent Clinical Trials for ATENOLOL; CHLORTHALIDONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federico II University	Phase 4
Agenzia Italiana del Farmaco	Phase 4
VA Office of Research and Development

See all ATENOLOL; CHLORTHALIDONE clinical trials

Pharmacology for ATENOLOL; CHLORTHALIDONE

Drug Class	Thiazide-like Diuretic beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for ATENOLOL; CHLORTHALIDONE

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for ATENOLOL; CHLORTHALIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	ATENOLOL AND CHLORTHALIDONE	atenolol; chlorthalidone	TABLET;ORAL	210028-001	Mar 8, 2019	AB	RX	No	No
Novitium Pharma	ATENOLOL AND CHLORTHALIDONE	atenolol; chlorthalidone	TABLET;ORAL	215560-002	Oct 25, 2021	AB	RX	No	No
Aiping Pharm Inc	ATENOLOL AND CHLORTHALIDONE	atenolol; chlorthalidone	TABLET;ORAL	072302-002	May 31, 1990	AB	RX	No	No

Expired US Patents for ATENOLOL; CHLORTHALIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	TENORETIC 100	atenolol; chlorthalidone	TABLET;ORAL	018760-001	Jun 8, 1984
Twi Pharms	TENORETIC 50	atenolol; chlorthalidone	TABLET;ORAL	018760-002	Jun 8, 1984
Twi Pharms	TENORETIC 100	atenolol; chlorthalidone	TABLET;ORAL	018760-001	Jun 8, 1984

ATENOLOL; CHLORTHALIDONE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Atenolol and Chlorthalidone?

Atenolol and chlorthalidone are longstanding antihypertensive agents. Their market presence is influenced by evolving clinical guidelines, patent statuses, and competition from newer therapies.

Atenolol Market Overview

• Product Profile: Beta-1 selective adrenergic blocker used primarily for hypertension and angina.
• Market Size (Global): Estimated at $1.3 billion in 2022 [1].
• Market Trends:
  • Declining use in several markets due to safety concerns related to long-term cardiovascular outcomes.
  • Increased prescribing of evidence-based alternatives like ACE inhibitors and ARBs.
  • Limited patent protection; generic versions dominate.
• Key Competitors:
  • Metoprolol, bisoprolol, and other cardioselective beta-blockers.
  • Combination products with other antihypertensives.

Chlorthalidone Market Overview

• Product Profile: Thiazide-like diuretic used for hypertension and edema.
• Market Size (Global): Estimated at $600 million in 2022 [2].
• Market Trends:
  • Revival in clinical interest following studies favoring chlorthalidone over hydrochlorothiazide for long-term cardiovascular risk reduction [3].
  • Availability as generic; no patent protections.
  • Increasing adoption in combination therapies.

Clinical Guideline Impact

• The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend chlorthalidone as a first-line therapy due to superior evidence in preventing cardiovascular events.
• Atenolol's role diminishes as evidence questions its long-term efficacy and safety for primary hypertension management.

Regulatory and Patent Considerations

• Both drugs are off-patent; generic competition determines pricing and market share.
• Patent expirations: Atenolol patents expired circa 2000, leading to a commoditized market.

What Is the Financial Trajectory for Atenolol and Chlorthalidone?

Revenue Trends (Past and Projected)

Drug	2019 Revenue ($M)	2022 Revenue ($M)	CAGR (2019-2022)	Comments
Atenolol	1,100	1,300	4.0%	Market stabilization; declining in some regions due to safety concerns.
Chlorthalidone	500	600	4.3%	Slight growth driven by guideline shifts and increased use in combination therapy.

Sources: IQVIA, 2022.

Price Dynamics

• Prices remain stable in mature markets due to generic competition.
• Potential price erosion exists if more biophysical or combination therapies gain prominence.

Future Revenue Drivers

• Increased switching to chlorthalidone for cardiovascular risk reduction offers upside.
• Atenolol's market is expected to decline as it is phased out in favor of alternatives supported by newer evidence.

Market Risks and Opportunities

• Risks: Declining prescriber preference, regulatory changes, and competition from fixed-dose combinations.
• Opportunities: Expansion into developing markets, formulation innovations, and combination products.

How Do Clinical Guidelines and Regulatory Changes Affect Market and Financial Outlook?

• The increased recommendation for chlorthalidone could drive volume growth, especially if formulary coverage favors it.
• Atenolol's declining status limits its future revenue potential.
• Regulatory bodies favor newer medications with proven long-term outcomes, reducing the attractiveness of existing drugs like atenolol.

How Is the Competitive Landscape Evolving?

• Alpha-beta blockers and other antihypertensives are gaining ground, driven by clinical trial data.
• Fixed-dose combinations are gaining popularity, presenting an opportunity for generic manufacturers.
• The rise of drug-eluting combination therapies reduces the demand for standalone agents.

What Are the Key Takeaways?

• Atenolol's market is mature, with declining growth potential due to safety profile concerns.
• Chlorthalidone benefits from renewed clinical support but faces standard generic market pressures.
• Both drugs' revenues are heavily influenced by prescribing trends, clinical guidelines, and regulatory preferences.
• Commercial strategies should focus on expanding use in line with evidence-based guidelines and innovation in delivery mechanisms.

FAQs

1. Why is the use of atenolol declining?
Clinical studies have shown atenolol to be less effective in reducing long-term cardiovascular events compared to other antihypertensives, prompting guidelines to favor alternatives such as ACE inhibitors or calcium channel blockers.

2. How does chlorthalidone compare to hydrochlorothiazide?
Chlorthalidone has a longer half-life and has demonstrated superior evidence for cardiovascular risk reduction in clinical trials, leading to increased preference in guidelines.

3. Are there patent protections remaining for these drugs?
No, both atenolol and chlorthalidone are off patent, resulting in generic-dominated markets and stable or declining prices.

4. What factors could influence future revenues?
Shifts in clinical guidelines, prescriber preferences, the emergence of combination therapies, and market expansion into developing regions.

5. How might regulatory changes impact these drugs?
New safety or efficacy data could result in updated prescribing restrictions or label changes, affecting demand and market share.

References
[1] IQVIA, 2022. Global pharmaceutical market data.
[2] Ibid.
[3] Bangalore S, et al. "Chlorthalidone versus hydrochlorothiazide in hypertension." JAMA Cardiology. 2017.